Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Literatur
1.
Florimonte L, Dellavedova L, Maffioli LS. Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging. 2016;43:1896–909.CrossRefPubMed
2.
Zlotta AR, Schulman CC. Can survival be prolonged for patients with hormone-resistant prostate cancer? Lancet. 2001;357:326–7. Commentary.CrossRefPubMed
3.
Deguchi T, Yang M, Ehara H, Ito S, Nishino Y, Takahashi Y, et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer. 1997;75:634–8.CrossRefPubMedPubMedCentral
4.
US Food and Drug Administration. FDA Public Workshop on Clinical Trial Endpoints in Prostate Cancer, 21–22 June 2004. Silver Spring, MD: US Food and Drug Administration. http://​www.​fda.​gov/​ cancer drug approval endpoints
5.
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.CrossRefPubMed
6.
Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;9:1084–6.CrossRef
7.
Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52:1721–6.CrossRefPubMed
8.
Kuroda I. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. Ann Nucl Med. 2014;28:11–6.CrossRefPubMed
9.
Holmes RA. [153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22:41–5.CrossRefPubMed
10.
Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer: a phase I/II trial. J Nucl Med. 1993;34:1839–44.PubMed
11.
Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1023–30.CrossRefPubMed
12.
Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31(1):171–8.CrossRef
13.
Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336–41.CrossRefPubMed
14.
Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79–86.PubMed
Metadaten
Titel
Radionuclide therapy of malignant bone lesions
verfasst von
M. Fischer
H. J. Biersack
Publikationsdatum
09.12.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3574-3

Weitere Artikel der Ausgabe 4/2017

European Journal of Nuclear Medicine and Molecular Imaging 4/2017 Zur Ausgabe

Original Article

18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience

Book Review

Michael Schuenke, Erik Schulte, Udo Schumacher (Editors): Atlas of anatomy: head, neck, and neuroanatomy

Original Article

The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer

Original Article

Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging

Editorial Commentary

Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium

Image of the Month

Diffuse 18F-FDG accumulation in the subarachnoid space detected by PET/CT in a patient with subarachnoid hemorrhage and hyperglycemia